Get notified when Lilly files — or if FDA acts
Retatrutide is investigational and not FDA-approved. Join this site’s email list for regulatory milestones. This is not an Eli Lilly waitlist, not a consumer queue at Lilly, and not exclusive launch pricing.
Weight-change figure is the Lilly efficacy estimand (21 May 2026). BLA plan: Lilly, 23 Jul 2026. Filing is not approval; no PDUFA date has been assigned.
Join the email list
We’ll email you when Lilly files a BLA or if FDA takes an action on retatrutide. This list is run by NextGenGLP1, not Eli Lilly.
What this list is — and isn’t
Filing and FDA updates
We’ll email you if Lilly submits a BLA or if FDA acts. A filing is not an approval, and no approval year has been announced.
Trial readouts
Stay informed with sourced Phase 3 updates. We label Lilly’s efficacy estimand when we quote weight-change figures.
Not a Lilly queue
Lilly has not announced a consumer waitlist. Joining here does not reserve a prescription, a pharmacy slot, or launch pricing.
Separate offer today
TrimRX is a compounded GLP-1 + GIP telehealth offer available today. It is not retatrutide and is not an FDA-approved branded product.
What the data actually says
Sourced Phase 3 figures, with the leftover Phase 2 “24%” labeled so it is not mistaken for Phase 3.
TRIUMPH-1, 12 mg, 80 weeks — Lilly efficacy estimand (21 May 2026). Treatment-regimen 12 mg was −25.0%. Not a head-to-head versus Zepbound.
Planned BLA filing — Lilly, 23 Jul 2026, reconfirmed 5 Aug 2026. CMC work is in progress. Filing is not approval. No PDUFA date.
GIP, GLP-1, and glucagon — investigational, no brand name. TRIUMPH-5 (NCT06662383) versus tirzepatide has not reported.
Phase 2 leftover “24%” — NEJM 2023, 48 weeks. That figure is not the Phase 3 lead result and should not be presented as if it were.
Note: Retatrutide is investigational and not FDA-approved. It is not for sale. Clinical trial results may not reflect individual outcomes. This page is informational, not medical advice. Talk with a licensed clinician before starting any medication.
Frequently Asked Questions
When will retatrutide be approved?
Unknown. Lilly plans a Q1 2027 BLA filing (23 Jul 2026; reconfirmed 5 Aug 2026). A filing is not an approval. No PDUFA date has been assigned, and we do not invent an approval year.
How much will retatrutide cost?
Unknown. Lilly has not announced a U.S. list price. This email list does not include exclusive launch pricing.
Is retatrutide better than tirzepatide?
They are different drugs. TRIUMPH-5 (NCT06662383), the Phase 3 head-to-head versus tirzepatide, has not reported. Do not treat cross-trial percentages as a ranking.
What are the side effects?
Phase 3 programs have reported gastrointestinal effects typical of incretins, plus dysesthesia (abnormal skin sensation) in some participants. That is not a complete safety list. Talk with a clinician.
Is this Lilly’s waitlist?
No. This is NextGenGLP1’s email list. Lilly has not announced a consumer waitlist. Joining here does not put you in a Lilly queue.
What is TrimRX doing on this page?
TrimRX is a separate compounded GLP-1 + GIP offer available today through a telehealth consult. It is not retatrutide, not Zepbound, and not Mounjaro. Compounded medication is not FDA-approved.
Want the FDA-path updates?
Join this site’s email list — not a Lilly program — for filing and decision news.
Join the email list